New York, NY. Elsevier, a global leader in research publishing and information analytics, is pleased to announce its market leading position in chemistry patent coverage and the extension of its collaboration with LexisNexis PatentSight. In March 2021, Elsevier launched its initiative to strengthen the existing patent coverage in Reaxys. The content expansion resulted in a 15-fold increase in patent coverage and ensures pharma and chemical companies and their researchers do not miss key competitive intelligence insights.
The number of discoverable patents in Reaxys now exceeds 30 million, and the Reaxys-PatentSight collaboration will further enhance content with the patents' ownership information. These insights will enable companies to better understand competitors' IP strategies, identify innovative players in a field and confidently assess the commercial viability of their projects.
Marco Richter, Global Head of Product, LexisNexis Intellectual Property Solutions, said:
"Competition is intense in R&D: With an increasingly diverse landscape of players in the pharmaceutical industry — from niche start-ups to emerging biotech companies, to academic research. To strengthen drug discovery capabilities and shorten development cycle, pharma companies often acquire specialized biotech companies or in-license drug candidates active in preclinical and clinical phases.
"Keeping up with the latest information about competitor IP activity and new research is a business-critical challenge. We are pleased to be continuing our collaboration with Elsevier to provide companies with more extensive information on IP history and understand that getting new drugs to market is a resource-intensive process for researchers and know our content can help accelerate this."
The Reaxys updates will enhance competitive intelligence by distinguishing "current patent assignee" and "original patent assignee" to track ownership over time, demonstrating which companies are most prominent in a particular field. Easy-to-use search filters will allow users to sort between inventors and current patent holders. Further enhancements to the patent assignee ontology that unify different common and legal names for corporations will be released in 2022. This allows companies to avoid blind spots and stay on top of emerging competitors when assessing the competitive landscape for a technology.
Dr. Ivan Krstic, Head of Chemistry Solutions at Elsevier added:
"Reaxys users want to clearly view current and past patent holders. These upgrades are in response to their feedback, and underlines our commitment to addressing user needs and responding in a timely manner with significant enhancements to the content and user experience. Because of this virtuous cycle, Reaxys has become the patent discovery space for chemists in pharma and chemical companies.
"This work underpins our vision to make Reaxys the most comprehensive, innovative and authoritative chemistry research information system that supports chemistry workflows and use cases, enabling the digital transformation that organizations need to achieve to help drive better research outcomes."
To find out more about the collaboration and patent coverage in Reaxys, visit the Reaxys website.
About LexisNexis Legal and Professional
LexisNexis Legal & Professional is a leading global provider of legal, regulatory and business information and analytics that help customers increase productivity, improve decision-making and outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis and Nexis services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 10,600 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
About LexisNexis Intellectual Property
LexisNexis Intellectual Property brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations and ultimately achieve a competitive advantage for their business. Our suite of workflow and analytics solutions (LexisNexis IP Data Direct, LexisNexis PatentAdvisor, LexisNexis PatentOptimizer, LexisNexis PatentSight and LexisNexis TotalPatent One) enables companies to be more efficient and effective at bringing meaningful innovations to our world. We are proud to directly support and serve these innovators in their endeavors to better humankind.
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.
In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.
Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier and LexisNexis are part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.